Dr. Michael C. Stiles, M.D.
Ophthalmology (Glaucoma Specialist (Ophthalmology) Physician)
- Medicare participating
At a glance
- Medical school
- University of Kansas School of Med (Kc/Wich/Sal) (1985)
- Years since graduation
- 41
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,225
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1985Medical school: University of Kansas School of Med (Kc/Wich/Sal)
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Glaucoma Specialist (Ophthalmology) Physician primary
KS license 04-21479 -
Ophthalmology Physician
KS license 0421479 · MO license R3N76
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Stiles Eyecare Excellence and Glaucoma Institute PA (5 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,225
- Services billed
- 4,572
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Exam of the internal drainage system of eye | 895 | 869 |
| Established patient complete exam of visual system | 570 | 546 |
| Imaging of optic nerve | 505 | 498 |
| Exam of visual field with extended testing | 485 | 475 |
| Established patient office or other outpatient visit, 30-39 minutes | 345 | 317 |
| Established patient office or other outpatient visit, 20-29 minutes | 322 | 257 |
| Established patient problem focused exam of visual system | 286 | 256 |
| Established patient office or other outpatient visit, 40-54 minutes | 268 | 253 |
| Photography of the retina | 240 | 239 |
| Removal of cataract with insertion of prosthetic lens | 170 | 103 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Latanoprost Other prescribers in Overland PArk, KS | 1,356 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Overland PArk, KS | 1,146 |
| Timolol Maleate Other prescribers in Overland PArk, KS | 665 |
| Prednisolone Acetate Other prescribers in Overland PArk, KS | 597 |
| Brimonidine Tartrate Other prescribers in Overland PArk, KS | 459 |
| Ofloxacin Other prescribers in Overland PArk, KS | 326 |
| Ketorolac Tromethamine Other prescribers in Overland PArk, KS | 296 |
| Combigan (brimonidine tartrate/timolol) Other prescribers in Overland PArk, KS | 294 |
| Lumigan (bimatoprost) Other prescribers in Overland PArk, KS | 292 |
| Dorzolamide Hcl Other prescribers in Overland PArk, KS | 218 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 29 payments worth $1,709 in total to this clinician.
| AbbVie Inc. | $784 |
|---|---|
| New World Medical,inc. | $372 |
| Alcon Vision LLC | $316 |
| Bausch & Lomb Americas Inc. | $136 |
| Tarsus Pharmaceuticals, Inc. | $27.00 |
| Sun Pharmaceutical Industries Inc. | $24.47 |
| Philips North America LLC | $19.32 |
| Sight Sciences, Inc. | $17.50 |
| Food and Beverage | $1,234 |
|---|---|
| Consulting Fee | $475 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Nov 12, 2025 | Consulting Fee XEN GLAUCOMA TREATMENT SYSTEM · EYE CARE | $475 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $36,195 in research payments for these studies, mostly to the institutions running them.
- The Hydrus Microstent New Enrollment Post-Approval Study: A Prospective, Non-Randomized, Multicenter, Single Arm Clinical Trial
Alcon Research LLC - A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
AbbVie Inc. · Recruiting · NCT06822738 - Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects …
Glaukos Corporation - Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma
AbbVie Inc. · Completed · NCT05411198 - Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.